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Background: Sarcoptic mange caused by the mite Sarcoptes scabiei is a worldwide disease affecting both humans
and animals. Here we report the molecular characterization and evaluation of a recombinant S. scabiei tropomyosin
(SsTm) protein in a vaccination trial in rabbits.
Methods: The full-length cDNA was cloned in a bacterial pET vector, and the recombinant protein was expressed
in BL21 (DE3) cells and purified. Using specific rabbit antiserum, tropomyosin was localized immunohistochemically
in mite tissue sections. Vaccination trials with the recombiant SsTm was carried out in New Zealand rabbits.
Results: The full-length open reading frame (ORF) of the 852 bp cloned gene from S. scabiei encodes a 32.9 kDa
protein. The amino acid sequence showed 98.94%, 97.89% and 98.59% homology to Dermatophagoides farina and
Dermatophagoides pteronyssinus group 10 allergens and Psoroptes ovis tropomyosin, respectively. Tropomyosin was
localized immunohistochemically in mite tissue sections mainly in the mouthparts, legs and integument of the
epidermis. The predicted cross-reactivity of SsTm indicated that it is an allergenic protein. While vaccination with
the recombiant SsTm resulted in high levels of specific IgG (P< 0.01), a low IgE antibody response and no
significant protection against S. scabiei challenge were observed. After challenge, specific IgG levels remained
significantly higher than the control (P< 0.01), while changes of total IgE levels were not significant (P> 0.05).
However, the lesion areas in the vaccination group decreased at the end of the experiment compared with
controls.
Conclusions: Although vaccination with recombinant SsTm did not efficiently control sarcoptic mange in rabbits,
the immunogenic properties of tropomyosin suggest it may be developed as a vaccine with alternative adjuvants
or delivery methods.
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Sarcoptic mange, caused by ectoparasite infestation with
the mite Sarcoptes scabiei, is a disease distributed world-
wide in both humans and animals. Overcrowded living
conditions, poverty and poor hygiene are significant fac-
tors [1] for infection with S. scabiei mites in the cur-
rently estimated 300 million people worldwide [2,3]. In
addition, Sarcoptes are common ectoparasites in domes-
tic and wild populations of canids, cats, ungulates, boars,
wombats, koalas, great apes and bovids [4]. In Spain,* Correspondence: guangyou1963@yahoo.com.cn
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reproduction in any medium, provided the orsarcoptic mange is a widespread disease in wild rabbits
[5]. The sarcoptes mites burrow into the epidermis and
lay eggs in the stratum corneum for weeks, leading to a
host immune response and antibody production and
resulting in papules on the surface of the skin and prur-
itus. Sarcoptic mange, if left untreated, may cause sig-
nificant morbidity and economic losses in livestock.
Moreover, high costs are associated with acaricides used
in infested livestock [6,7].
Although various acaricides considered as appropriate
treatments are generally used to control sarcoptic mange
[8], they can be highly toxic and strong resistance to
them can be developed. Furthermore, the quality and
safety of livestock products are threatened with theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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acaricides [9]. Thus, the Sarcoptes World Molecular
Network (WMN) [10] was established to coordinate and
support additional epidemiological, diagnostic, treatment
and molecular studies of scabies mites.
Tropomyosin, a microfilament protein with a ɑ-helical
coiled-coil structure, is found in all cell types [11]. It has
been identified as a conserved and cross-reactive allergen
between mites and other invertebrates [12]. Therefore,
tropomyosin is considered as a good model to study the
contribution of the primary structure to the allergenicity of
proteins [13]. Previous studies have shown that the group
10 tropomyosin allergen of house dust mites induces
cross-reactivity of IgE and reacts with specific IgE from
humans allergic to these allergens [14]. In addition, the
tropomyosin allergen is present in shrimp, mites and
insects, and may serve as a potential vaccine candidate
antigen along with myosin and paramyosin [15], [16]. Suc-
cessful vaccination with recombinant tropomysin has been
reported in other parasites. For instance, immunization
with a tropomyosin-like protein purified from the rodent
filarial Acanthocheilonema viteae was shown to decrease
the number of adult worm burden by up to 65% as well as
the circulating microfilariae by up to 93% in jirds (Mer-
iones unguiculatus) [17]. Furthermore, tryopomyosin is
confirmed as an immunodominant allergen of sheep scab
mites and shows promise as a vaccine candidate [18,19].
In this study, we isolated the tropomyosin gene of Sar-
coptes scabiei based on analysis of expressed sequence
tags (EST). The recombinant protein (SsTm) was
expressed, analyzed and purified for immunization of
rabbits. Immunolocalization of tropomyosin in S. scabiei
tissues was also performed.
Methods
Mites and animals
Sarcoptic mites (adults, nymphs and larvae) were col-
lected from rabbits and stored at −70°C prior to RNA
extraction. Mites were unfed prior to treatment. Four-
month-old naive rabbits were prepared for a vaccination
trial at the Laboratory Animal Center of Sichuan Agri-
culture University (China). All animals were handled in
strict accordance with animal protection laws of the
People's Republic of China (A draft of an animal protec-
tion law in China was released on September 18, 2009).
All procedures were strictly carried out according to the
Guide for the Care and Use of Laboratory Animals.
Isolation of total RNA and amplification of cDNA
encoding tropomyosin
Extraction of total RNA was carried out using a com-
mercial extraction kit (Waston, Shanghai, China) and
transcribed into cDNA using RevertAidTM First Strand
cDNA Synthesis Kit (Fermentas) according to themanufacturer’s protocol and stored at −70°C. Based on
the S. scabiei EST database [20], the foward (5'-ATG
GAGGCCATCAAGAAAAAAATG-3') and reverse (5'-
TTAATAACCAGTAAGTTCGGCAA-3') primers were
used in a reaction mixture containing 5 μL cDNA in a
total of 50 μL. The cycling parameters were 94°C for
5 min and 94°C for 45 sec, followed by 30 cycles of 49°C
for 45 sec, 72°C for 45 sec and a final extension of 72°C
for 10 min. PCR products were separated by agarose gel
electrophoresis (2% TAE-agarose gel) and purified with a
QIAquick Gel Extraction Kit (Watson) according to the
manufacturer’s instructions.
Expression and purification of recombinant tropomyosin
The full-length coding sequence was amplified by PCR
using specific primers (forward primer 5’-CATGC-
CATGGATGGAGGCCATCAAGAAA-3’; reverse primer
5‘-CGGGATCCTTAATAACCCATAAGTTC3-’). The PCR
products were digested with BamH I and Nco I (TaKaRa,
Tokyo, Japan) and gel-purified. The cDNA was subcloned
into the bacterial expression vector pET-32a (+) (Novagen,
Dermstadt, Germany) and used to transform BL21 (DE3)
Escherichia coli cells (Novagen). Briefly, individual colonies
were selected and grown in LB medium with ampicillin
(50 μg/ml) at 37°C until the OD600 value reached 1.0,
and then isopropyl-beta-d-thiogalactopyranoside (IPTG)
was added at the final concentration of 1 mM to in-
duce recombinant protein expression for 4 h at 37°C.
Purification of the recombinant SsTm was performed as
previously described [21].
Sequence analysis and cross-reactivity prediction
The presence of a signal peptide was detected using
SignalP-2.0 at the Center of Biological Sequence Ana-
lysis (http://www.cbs.dtu.dk/services/SignalP-2.0/), and
cellular localization was predicted using TMHMM
(http://www.cbs.dtu.dk/services/TMHMM/). The mole-
cular weight of the predicted protein was calculated
using Compute pI/Mw (http://us.expasy.org/tools/pi_
tool.html). Cross-reactivity with known allergens was
predicted with the web server SDAP (http://fermi.utmb.
edu/SDAP/).
Western blotting
For Western blotting, recombinant SsTm proteins were
separated by electrophoresis and subsequently trans-
ferred onto a PVDF membrane (Millipore, Dermstadt,
Germany) for 1 h in an electrophoretic transfer cell
(Bio-Rad, Hercules, California,USA). The membrane was
blocked with 5% skimmed milk in TBST (40 mM Tris–
HCl, 0.5 M NaCl, 0.1 Tween-20, pH 7.4) for 4 h at room
temperature. Subsequently, the membrane was incu-
bated with rabbit antiserum diluted 1:200 (v/v) in 1%
skimmed milk-TBST overnight at 4°C. The membrane
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incubated with alkaline phosphatase-conjugated goat
anti-rabbit IgG diluted 1:1000 for 1 h. After another
three washes for about 10 min each time with TBST,
protein signals were detected using 5-bromo-4-chloro-
3'-indolyphosphate (BCIP) and nitro-blue tetrazolium
(NBT) substrates.
Immunolocalization of tropomyosin
In order to perform immunolocalization studies of mite
sections, antiserum against SsTm were raised in rabbits
using standard procedures [22]. Mites were fixed in 1%
molten agarose and set in paraffin wax after solidification
of the molten agarose. Briefly, 5 μm sections were cut,
dried at 60°C, dewaxed, rehydrated, treated to inactivate
endogenous peroxidase and incubated in 25% normal
goat serum in TBS for 15 min. Thereafter, the tissue sec-
tions were incubated at 4°C overnight with specific rabbit
anti-SsTm antibodies diluted 1:1000 in TBS. After the
sections were rinsed with TBS, horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (AMRESCO,
Texas, USA) diluted 1:200 was used for detection of the
antibodies and visualized using the EnVision TM+ Sys-
tem, HRP (DAB) (DAKO, Glostrup, Denmark). Sections
were counterstained with hematoxylin and rinsed in
water and dehydrated. Finally, sections were mounted in
a resin-based mountant and viewed with a microscope.
Negative controls were carried out by replacement of
specific antibodies with negative rabbit serum.
Vaccination trial
Preparation of the challenge inoculum of S. scabiei mites
was designed similarly to that described previously [23].
Number of rabbits per group was designed similarly to a
study of S.scabiei challenge trial [24]. Eighteen female
New Zealand rabbits, about 4 months of age, were ran-
domly divided into three groups (6 rabbits per group).
Animals were immunized as follows: group 1, 100 μg
SsTm mixed with 100 μg QuilA(0.01 g/ml, International
Laboratory, USA); group 2, 100 μg QuilA in normal sa-
line (NS) as adjuvant controls; group 3, only NS as un-
vaccinated controls. All animals were immunized four
times by hypodermic injection at 1-week intervals for
the first three times and a 2-week interval before the last
vaccination. Two weeks after the last vaccination, the
rabbits were challenged with approximately 2000 live
mites each on the convex surface of the left ear for 48 h
maintained by a piece of gauze. Blood samples were
taken prior to vaccination, every week during vaccin-
ation and challenge until week 4 post-challenge. Skin
lesions were photographed weekly after challenge.
Mange lesion areas and the body weights were measured
during the vaccination trial every week. The lesions were
graded as follows: score 0 if no area was infected; score1 if <10% of the area was infected; score 2 if 10–25% of
the area was infected; score 3 if 25–50% of the area was
infected; score 4 if 50–100% of the area was infected.
Enzyme-linked immunosorbent assays (ELISA)
Serum samples were collected from immunized and
control rabbits for assessment of antibody responses.
Specific IgG and total IgE levels against SsTm were
determined by ELISA. Purified SsTm was used to coat
96-well ELISA plates (Invitrogen, Carlsbad, California,
USA) at 4 °C overnight in 50 μl of carbonate buffer
(0.06 M, pH 9.6). The plates were washed with PBS con-
taining 0.05 % Tween-20 (PBST) four times and then
blocked with 100 μl of 1% BSA in PBS and incubated at
37 °C for 1 h. After the wells were washed again with
PBST, 100 μl of sera (1:100) were added to the wells and
incubated at 37 °C for 1 h. The wells were washed four
times with PBST and incubated with HRP-conjugated
goat anti-rabbit IgG (1:5000) at 37°C for 1 h. Following
the final wash cycle, the wells were incubated with 50 μl
TMB substrate (45 mM dibasic sodium phosphate,
0.22 mM citric acid, 0.42 mM 3, 3', 5, 5'tetramethylben-
zidine and 30% H2O2), and the reaction was stopped
after 15 min by adding 50 μl per well of 0.5 M H2SO4.
The optical density (OD) was measured at 460 nm using
a microplate reader. Total IgE levels were measured
using a rabbit IgE ELISA kit (Groundwork biotechnology
Diagnosticate, USA) according to the manufacturer’s
instructions.
Statistical analysis
Statistical analysis was performed by analysis of variance
(ANOVA), Dunnett’s test and least significant difference
(LSD) using SPSS version 13.0 for Windows. Differences
with P-values < 0.05 were considered statistically
significant.
Results
Amplification of cDNA encoding tropomyosin
A cDNA sequence was obtained with an open reading
frame of 852 bp (GenBank: JF922117) encoding a 284
amino acid tropomyosin protein. By phylogenetic ana-
lysis, this tropomyosin sequence from scabies mites
showed high homology to that of Dermatophagoides
farinae (Der f 10) (83.90%), Dermatophagoides pteronys-
sinus (Der p 10) (85.26%), Psoroptes ovis (85.03%) and
other arthropods (e.g. Boophilus microplus, Haemaphy-
salis longicornis, Lepidoglyphus destructor) (72%-82%).
Other tropomysin sequences in the tree from nema-
todes, trematodes, fish and ticks all formed separate and
distinct clades (Figure 1). The protein was predicted to
have a molecular weight of 32.90 kDa, a pI = 4.43, as well
as strong hydrophobicity and antigenicity. No signal
peptides or transmembrane domains were evident in the
Figure 1 Neighbor-joining phylogenetic tree of selected
tropomyosin proteins. GenBank accession numbers for each
sequence are as follows: Homarus americanus, AF034954;
Haemaphysalis longicornis, AF534184; Dermatophagoides
pteronyssinus, D17682; Dermatophagoides gallinae, AM167555;
Schistosoma japonicum, L76203; Boophilus micoplus, AF124514;
Psoroptes ovis, AM114276; Anisakis simplex, Y19221; Lepidoglyphus
destructor, AJ250096; Haliotis asinina, AY320360; Sarcoptes scabiei,
JF922117. The percentage of support from 1000 bootstrap replicates
is indicated at the nodes. Phylogenetic analysis was conducted
using MEGA 4.0 [25].
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anchored to a cellular membrane. An alignment of SsTm
with other tropomysin proteins is shown in Figure 2.
The amino acid sequence of SsTm is rich in Glu
(20.4%), Ala (12.0%) and Lys (9.9%) and highly homolo-
gous to Der f 10, Der p 10 and P. ovis tropomyosin with
identities of 98.94%, 97.89% and 98.59%, respectively.
Prediction of cross-reactivity
A FASTA alignment was used to identify whether the
SsTm protein is potentially cross-reactive based on the
Food and Agricultural Organization (FAO)/World
Health Organization (WHO) allergenicity rules. The
results showed that SsTm is related to 4 allergenic pro-
teins from 4 species of mites (Table 1). The most hom-
ologous protein in the Structural Database of Allergenic
Proteins (SDAP) to SmTm was found to be Tyr p 10
(Tyrophagus putrescentiae) from a storage mite (E < 0.01).
Expression of recombinant SsTm and Western blot
analysis
SDS-PAGE analysis showed that the molecular weight of
the expressed protein was approximately 50 kDa, con-
sisting of the predicted 32.9 kDa SsTm protein and an
additional peptide expressed from the pET-32a (+) vec-
tor (20 kDa). The recombinant SsTm was confirmed tobe a soluble protein. Furthermore, the results showed
that the maximum expression of recombinant SsTm was
obtained at 37°C at 4 h after induction with 0.4 mol/L
IPTG (data not shown). The recombinant SsTm was
detected in Western blots by serum raised in rabbits
against S. scabiei (Figure 3), while no reaction was
observed when using the negative control serum (data
not shown).
Immunolocalization
The staining was evidently widespread in mites, particu-
larly in the mouthparts and legs. The SsTm protein also
appeared in the integument of epidermis and stomach
muscle (Figure 4). No staining was detected in sections
of S. scabiei developed with pre-immune serum (data
not shown).
SsTm vaccination trial in rabbits
The protective effects of recombinant SsTm in rabbits
against S. scabiei was identified by measuring the
infested areas (Table 2). Forty-eight hours after chal-
lenge, inflammation in almost all of the infected auricles
of the rabbits and a number of small papules were
observed when the auricles were palpated. No differ-
ences were observed among the three groups in lesion
levels. Over the course of infection, the papules were
replaced by crusts in all rabbits, and the infested areas
increased rapidly. At the end of the trial, margins of the
infected auricles were covered by thick crusts in some
rabbits. Although the mange lesions did not spread to
limbs, many mites were detected in skin scrapings from
rabbits in the three groups (data not shown). Interest-
ingly, the lesion areas in vaccinated groups were appar-
ently reduced compared with NS control groups at the
end of the experiment. However, it was difficult to dis-
tinguish between the vaccinated group and controls by
identifying the severity of lesions.
Serological responses to SsTm vaccination were evalu-
ated by ELISA (Figures 5). Scabies-specific IgG anti-
bodies increased after the first immunization in all the
vaccinated animals (P < 0.001), which were significantly
higher than the levels observed in QuilA groups and
non-vaccinated groups (P < 0.001). The levels of scabies-
specific IgG antibodies peaked (OD450 2.02) at the fifth
week and stabilized at high levels after challenge in the
vaccinated groups. In the QuilA and non-vaccinated
groups, the OD450 values of specific IgG remained low
throughout the experiment. Due to the lack of an effect-
ive secondary anti-rabbit IgE antibody, we chose to
measure the levels of total IgE, which did not change ob-
viously after the four immunizations compared with the
levels of pre-immune serum in all animals. In the four
weeks after challenge, IgE levels of the unvaccinated
group and QuilA group increased slightly, but the OD450
Figure 2 Comparison of SsTm with the tropomyosin amino acid sequences of other species. Genebank accession numbers: A. simplex,
CAB93501; B. microplus, AAD17324; Der f 10, BAA04557; Der p 10, CAJ44440; L. destructor, CAB71342; P. ovis, CAJ38272; S. scabiei, JF922117.
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cant difference was observed between the SsTm group
and saline group (P > 0.05). However, specific antibody
titers decreased slightly at weeks 9 and 10 and may be
associated with the reduced lesion areas in the vacci-
nated group.
Discussion
In this study, we described the molecular charact-
erization of tropomyosin from Sarcoptes scabiei and
evaluated its ability to induce protection against infec-
tion in rabbits. An EST study of S. scabiei has identifiedTable 1 Predicted cross-reactivity between SsTm and known
No Allergen Accession Species
1 Tyr p 10.0101 ABQ96644 Storage mite
2 Der f 10.0101 ABU97468 American house du
3 Der p 10 CAA75141 European house du
4 Blo t 10.0101 ABU97466 mite
aThe bit score is equivalent to the bit score reported by BLAST. A 1-bit increase in s
implies 1000-fold lower expectation. Sequences with E values < 0.01 are almost alwthe presence of a sequence with high homology to the
Mag44 sequence in dust mites [20]. Here, we success-
fully cloned and expressed SsTm encoded by the tropo-
myosin gene, and this protein revealed high homology to
group 10 allergen of storage mites, group 10 allergen of
house dust mites and P. ovis tropomyosin. Group 10
house dust mite allergen is conserved and cross-reactive
with tropomyosin of species such as shellfish and other
arthropods [26]. Furthermore, patients who are allergic
to house dust mites show clinical symptoms when eat-
ing shellfish [27]. The prediction of cross-reactivity
indicated a highly significant sequence match of SsTmallergens in SDAP
Sequence Length bit scorea E score
284 33.9 3.7e-03
st mite 289 33.7 4.4e-03
st mite 284 33.1 6.4e-03
284 32.9 7.3e-03
core corresponds to a 2-fold reduction in expectation, and a 10-bit increase
ays homologous.
Figure 3 Western blotting analysis of recombinant proteins.
M, protein marker; lane 1, purified recombinant proteins; lane 2,
Western blot results.
Table 2 Mean mange lesion scoresa after challenge
prior to
challenge
week 1 week 2 week 3 week 4
unvaccinated group 0 2.08±0.39 2.36±0.16 2.7±0.10 3.06±0.10
SsTm group 0 1.96±0.34 2.67±0.32 3±0.26 2.74±0.19
QuilA group 0 2±0.13 2.88±0.24 3.5±0.56 3.68±0.10
aThe lesions were graded as follows: score 0 if no area was infected; score 1 if
<10% of the area was infected; score 2 if 10–25% of the area was infected;
score 3 if 25–50% of the area was infected; score 4 if 50–100% of the area was
infected.
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not a specific allergen for Sarcoptic mites and may
have high cross-reactivity with tropomysin of other
mites and invertebrates [28].
In this study, SsTm was localized by immunohisto-
chemistry in the mouthparts, muscle and legs of scabies
mites, as similarly observed in P. ovis [19]. As an actin-
binding protein, tropomyosin can stabilize actin fibersFigure 4 Immunolocalization of tropomyosin in sections of S. scabiei.
(pre-immune sera). The EnVision TM+ System-HRP(DAB) (DAKO) was used,
antibodies. M, mouthparts; L, legs; S, stomach blocks; IE, the integument ofand plays an important role in development and activ-
ities of vertebrates [11]. Moreover, the mouthparts and
legs of mites are important organs for feeding and bur-
rowing. Hence, it is possible that the function of tropo-
myosin is related to the survival activities of S. scabiei.
Many studies have identified tropomyosin as a highly
allergenic protein from parasites, such as nematodes
[29], trematodes [30] and mites [31], and it induces Th2-
IgE mediated responses in sheep infested with the sheep
scab mite [18]. Furthermore, specific IgG and IgE anti-
body levels have been shown to be dramatically
increased in rabbits and goats exhibiting signs of sarcop-
tic mange [31,32]. In addition, IgE is also an important
antibody in the host defense against scabies mites [32].
Although the whole mite extracts have been used in
studies of S.scabiei vaccination trials recently, abundant
mites are difficult to acquire owing to the lack of an
in vitro culture system [6]. Furthermore, tropomyosin
has been demonstrated to effectively induce protective
responses against other parasites such as the filarial
nematode A. viteae as mentioned above. The troponin I-
like protein of Haemaphysalis longicornis, which has
been considered as a potential vaccine candidate antigen,
may be identical to tropomyosin [33]. Hence, we chose
the recombinant protein as a potential candidate anti-
gen. In the previous studies, we stopped the experiment
four weeks after infestation because scabies mange of(A, B) Staining with anti-tropomyosin as primary antibody. (C) Control
according to the manufacturer’s instructions for detection of the rabbit
epidermis; A, anterior end of mite; P, posterior end of mite.
Figure 5 Specific IgG(A) and IgE(B) antibody levels in sera of rabbits immunized with S. scabiei tropomyosin detected by ELISA. Rabbits
were vaccinated four times with SsTm, QuilA and saline and challenged with approximately 2000 mites. Results are shown as means (± S.D.). OD
values were determined as absorbance at 450 nm. V1, first vaccination; V2, second vaccination; V3, third vaccination; V4, fourth vaccination.
*P< 0.01, compared with NS control group.
Zhang et al. Parasites & Vectors 2012, 5:176 Page 7 of 9
http://www.parasitesandvectors.com/content/5/1/176rabbits may cause devastating effects of fitness in the
short-term [34]. Furthermore, lesion areas could hardly
be measured if mites transferred throughout the body of
the rabbit such as limbs and head. In this study,
immunization of rabbits with recombinant SsTm in the
present study did not provide significant protection
against S. scabiei challenge, although a high level of spe-
cific IgG and a decrease in lesion areas were elicited.
Findings of two previous vaccination studies [24,35] with
insoluble and soluble mite protein fractions in goats
infested with S. scabiei var. ovis revealed that the
responses did not have any protective value. We
obtained a similar result to the latter study in which vac-
cination with the soluble protein fraction induced highlevels of scabies-specific IgG but failed to induce a sig-
nificant level of specific IgE. Vaccination with soluble re-
combinant SsTm in this current study likewise did not
generate evident levels of IgE in rabbits. Conversely,
goats that received repeated mite challenge have been
shown to develop strong IgG and IgE antibody responses
[23]. Another report showed that extremely high total
IgE and IgG levels were induced in the serum of crusted
scabies patients [36]. In the current study, a significant
rise in specific IgG antibody was detected in vaccinated
animals compared to the control animals, but the total
IgE antibody level was not obviously elevated within four
weeks after the challenge. Thus, low IgE levels may ei-
ther indicate that SsTm truly had little effect or that the
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of this protein to be observed.
IgG responses against whole S. scabiei antigen extracts
have been using to diagnose sarcoptic mange in pigs
[37] and also to evaluate protective effects via serum
IgG and IgE responses in a vaccination trial against S.
scabiei. In another previous study, it was suggested that
the mite densities after challenge in animals vaccinated
with fresh mite extracts were considerably lower than
those in control animals, although skin lesions were still
obvious in all goats [38]. Hence, our results indicate that
antibodies induced by SsTm may not be the effective re-
sponse needed for protection. Another similar vaccin-
ation study of Ssag1 and Ssag2 in rabbits showed no
protective effect, although the immunized rabbits did
not exhibit the typical crust characteristics [39]. Never-
theless, differences in lesion characteristics were not ob-
vious between the vaccinated and unvaccinated groups
in our study. It seems that the allergenicity of SsTm was
too low to induce adequate protective immunity or per-
haps subtle structural changes of recombinant SsTm led
to a loss of allergenicity and ability to generate a protect-
ive immune response. Due to the lack of immunization
studies against S. scabiei with recombinant mite pro-
teins, it is unclear why tropomyosin has been identified
as an allergenic protein but not when isolated from
mites.
The immune response mechanism of scabies mites
remains unclear despite the attention this field has
received by many researchers. Cell-mediated immunity
has been shown to be principally involved but antibodies
are also relevant immune responses induced by
immunization against scabies mites [40]. Unlike other
ectoparasites, which live on the skin surface of the host,
scabies mites thrive in the epidermis of the host and feed
on epidermal proteins and host plasma. It is possible
that the low level of protective immunoglobulin is
ingested into the gut or that tropomyosin is not the tar-
get of protective immunity in S. scabiei. Multiple studies
on the specific mechanisms of immune evasion in sca-
bies mites have shown a multigene family of inactivated
scabies mite serine proteases (SMIPPs) to be responsible
for the adaptation to parasitism in the epidermal bur-
rows, and these proteins may also have an influence on
protective efficacy [41], [42].
Conclusions
In summary, we have characterized an allergenic protein
SsTm from S. scabiei by demonstrating its localization in
muscle tissues, mouthparts and legs, and implicated its
potentially significant functional role in S. scabiei. Al-
though, no significant protective effect was detected
against mite challenge in rabbits vaccinated with recom-
binant SsTm, multiple vaccination studies have suggestedthat tropomyosin should be evaluated for its vaccine po-
tential. This study established a foundation for further re-
search on recombinant vaccines in scabies mite. Clearly,
future studies should focus on development of more ef-
fective methods to enhance the protective efficacy of re-
combinant vaccines against sarcoptic mange.
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